67 results about "Solid Dose Form" patented technology

The present disclosure relates to solid dose formulations for needle-free delivery comprising 0.01 to 60 (w / w) of one or more therapeutic agent and / or prophylactic agent; and 40.0% to 99.99% (w / w) of dextran. The invention further concerns methods of producing a solid dose formulation tablet and application its particular medical uses, in particular as a vaccine.

Disclosed herein are pharmaceutical oral solid dosage forms comprising a salt of liothyronin and a salt of levothyroxine, and methods of making and using the pharmaceutical oral solid dosage forms.

Described herein are dosage forms comprising the compound:wherein the dosage form can be a solid dosage form, a liquid dosage form, or a solid amorphous dispersion.

Provided herein are pharmaceutical formulations of a therapeutically effective amount of (R)-N-(1-hydroxypropyl-2-yl)-5-(4-(trifluoromethyl) phenoxy)-2-naphthamide in a solid dosage form. Also provided herein are methods of treating cancer comprising a pharmaceutical formulation of a therapeutically effective amount of (R)-N-(1-hydroxypropyl-2-yl)-5-(4-(trifluoromethyl) phenoxy)-2-naphthamide in a solid dosage form.

The present invention relates to formulations of elafibranor or a pharmaceutically acceptable salt or ester thereof; and uses thereof. In particular, the present invention relates to an oral solid dosage form comprising at least elafibranor or a pharmaceutically acceptable salt or ester thereof; a filler, a disintegrating agent and a binder.

This invention relates to pharmaceutical inclusion compounds, their preparation methods, and uses. Specifically, it provides a buggerfuran inclusion compound and its preparation method, wherein the inclusion compound comprises buggerfuran, cyclodextrin compounds, and optionally a high molecular weight polymer. This inclusion compound has a simple composition, high encapsulation efficiency, stability, and high safety, and can be used to prepare various liquid and solid dosage forms.

A solid dosage form for oral transmucosal delivery of an active pharmaceutical ingredient (API) is disclosed. Also provided are methods of treating a disease with the solid dosage form.

Disclosed in certain embodiments is a system and method of providing a dronabinol oral solid dosage form with increased stability.

The present disclosure relates to oral dosage forms comprising an antiviral nucleoside and one or more excipients, wherein the oral dosage form is a tablet. The antiviral nucleoside is selected from a prodrug of beta-D-N (4)-hydroxycytidine (I), such as 2-methylpropionic acid {(2R, 3S, 4R, 5R)-3, 4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3, 4-dihydropyrimidin-1 (2H)-yl] oxacyclopentane-2-yl} methyl ester)-compound (A), or a pharmaceutically acceptable salt, tautomer or prodrug thereof. (I) (A)

Composition, in particular pharmaceutical composition, in the form of a fixed dosage (solid dosage form) for sucking and / or chewing, preferably for sucking, in particular lozenge, preferably for use in the prophylactic and / or therapeutic topical (local) treatment of inflammatory diseases of the mouth and throat, wherein the composition contains an effective, in particular pharmaceutically and / or therapeutically effective, amount of an active ingredient preferably suitable and / or effective for the topical (local) treatment of inflammatory diseases of the mouth and throat, in particular with antiseptic and / or antimicrobial properties, preferably with antibacterial and / or antiviral and / or antifungal properties, wherein the active ingredient is incorporated and / or embedded in a solid matrix, wherein the composition, in particular the solid dosage form and / or the matrix, releases the active ingredient upon topical (local) application and / or use, preferably by sucking and / or chewing, preferably by sucking, in the oral and pharyngeal cavity; wherein the active ingredient is octenidine, in particular in the form of a pharmaceutically compatible and / or physiologically acceptable salt or ester, preferably in the form of a pharmaceutically compatible and / or physiologically acceptable salt, particularly preferably octenidine dihydrochloride; and wherein the composition, in particular the solid dosage form and / or the matrix, furthermore and / or additionally contains at least one further ingredient (a) and / or (b), in particular (a) and (b), wherein the at least one further ingredient (a) and / or (b) is selected from the group of (a) Flavor modulators, in particular selected from the group of the following components (i), (ii) and / or (iii): (i) Bitter (taste) masking agents, in particular selected from the group consisting of bitter taste receptor antagonists, preferably 4-(2,2,3-trimethylcyclopentyl)butanoic acid, and saponins, preferably glycyrrhizic acid (glycyrrhizin) and its salts or esters and / or glycyrrhetinic acid (glycyrrhetin) and its salts or esters, complexing agents, in particular cyclodextrins, and combinations or mixtures thereof, (ii) Bitter substances, in particular coffee extract and / or tea extract and / or their respective bitter substances, preferably coffee extract and / or its bitter substances, (iii) preferably natural or nature-identical (aroma) oils and / or essential oils, in particular with antiseptic and / or antimicrobial properties, preferably with antibacterial, antifungal and / or antiviral properties, in particular selected from the group of anise oils, in particular star anise oil, peppermint oil, eucalyptus oil, lavender oil, tea tree oil, chamomile oil, clove oil, rosemary oil, caraway oil, cinnamon oil, sage oil and fennel oil, as well as combinations or mixtures thereof; in particular wherein the ingredient (a) and / or the flavor modulator comprises a combination of at least two different components (i), (ii) and / or (iii), preferably a combination of components (i), (ii) and (iii); (b) Acidulants, in particular saliva-stimulating and / or flavor-enhancing acidulants, preferably acidulants authorized under pharmaceutical and / or food law and / or acidulants authorized as pharmaceutical additives and / or food additives, in particular selected from the group of tartaric acid and its salts, in particular sodium tartrate, sodium potassium tartrate (Rochelle salt) and calcium tartrate, citric acid and its salts, metatartaric acid, fumaric acid, ascorbic acid, phosphoric acid and its salts, stannous chloride, in particular tin(II) chloride, malic acid, lactic acid, adipic acid, succinic acid and other pharmaceutically compatible and / or physiologically acceptable organic acids and their salts, as well as their combinations or mixtures.

The present disclosure provides a solid dosage form for customized release of a nutraceutical, wherein the solid dosage form comprises a plurality of tablets in a single capsule, wherein at least one tablet of the plurality comprises a dose of the nutraceutical. Also provided herein are methods for improving bioavailability of a nutraceutical in a subject by administering a solid dosage form described herein.

The present invention relates to co-treated excipient compositions for solid dose pharmaceutical formulations. In addition, the present invention relates to a process for preparing the co-treated excipient composition and a solid dose pharmaceutical formulation containing the co-treated excipient composition.

Provided herein are compositions and methods relating to solid dosage forms comprising an absorption enhancer. The composition enhances mucosal penetration and absorption of the active ingredient.

The invention provides a rotary die mold process for manufacturing softgel capsules incorporating another solid form within said capsule and wherein said softgel capsule is free of air bubbles, in which at least two material strips are brought together by means of counter-running forming rolls and formed into capsules, a liquid and solid filling material being introduced via a filling wedge segment comprising two concave wedge surfaces; a filling medicine inlet; a fill medicine outlet; an output of solids and pre-fill medicine; a solids feed channel and pre-fill medicine; a pre-filling medicine inlet and a solids inlet. A softgel capsule free of air bubbles having incorporated within said capsule a second solid form, said second solid form being the form of a tablet.

A sieve guide assembly and a method of fractionation using a sieve guide assembly comprising a circular sieve screen (190) and a sieve guide 310 mountable in a fractionating device for fractionating granules for solid dosage forms, such as tablets, capsules or sachets, wherein the fractionating device comprises a drive adapted for: (i) in combination with a sieve screen without a sieve guide, inducing a lateral flow of granules defining lateral streamlines 31a.1. 31b.1, 31c.1, 31d.1 and an orbital flow defining orbital streamlines 31a.2. 31b.2, 31c.2, 31d.2, 31d.3 on the sieve screen (190), and (ii) in combination with the sieve guide assembly, inducing a guided lateral flow of granules defining guided lateral streamlines (331.3) and a central guided orbital flow defining central orbital streamlines (331.2) on the sieve screen (190), whereby the sieve guide assembly is adapted to provide a uniform, controlled and effective exposure of the granules to the sieve screen.

The present disclosure relates to oral dosage forms of pharmaceutical formulations that comprise an antiviral nucleoside, one or more compression aids, one or more glidants, and one or more lubricants, and one or more disintegrants, wherein the oral dosage form is a pellet having a diameter of less than or equal to 4.0 mm.

The present invention relates to the use of co-processed excipients in continuous manufacturing of solid dosage forms.

To provide a solid pharmaceutically acceptable formulation of daptomycin having an improved reconstitution time.SOLUTION: This solid formulation comprises daptomycin, arginine, histidine, and at least one branched aliphatic amino acid selected from the group consisting of leucine, isoleucine, valine, and pharmaceutically acceptable salts thereof. In the solid formulation, the molar ratio of the at least one branched aliphatic amino acid to daptomycin is from 0.5:1 to 5:1.SELECTED DRAWING: None

A closed-system grinding syringe (10, 110) is provided for liquefying and delivering a solid dosage form (20), including a barrel (22), a fluid port (30) disposed on a bottom wall (28) of the barrel (22), and a plunger (32). A head (36) of the plunger (32) is insertable into and moveable within the barrel (22) such that (a) a portion of the barrel (22) defines a closed-system syringe chamber (46) between the bottom barrel wall (28) and a lower surface (64) of the plunger head (36), and (b) a plunger-head annular seal (42) forms a fluid-tight seal between an outer surface (44) of the plunger head (36) and a cylindrical inner surface (26) of the barrel (22). A solid-dosage-form support disc (60, 360) is disposed below a bottom plunger wall (38) so as to define a grinding compartment (62) between the lower surface (64) of the bottom plunger wall (38) and an upper surface (66) of the solid-dosage-form support disc (60, 360), and is shaped so as to define a plurality of holes (68, 368) through the solid-dosage-form support disc (60, 360).

The invention relates to the field of medicine, in particular to solid dosage forms for the treatment of primary biliary cholangitis (PBC). The invention provides a modified release solid dosage form comprising two active pharmaceutical ingredients, obeticholic acid and ursodeoxycholic acid, arranged to release sequentially over time. The solid dosage form is designed to achieve a controlled, separate release of each API to provide a desired therapeutic profile.

Oral solid dosage forms including porcine thyroid powder and methods of making and using the oral solid dosage forms are disclosed.

A pharmaceutical formulation in solid dosage form of a therapeutically effective amount of (R)-N-(1-hydroxypropan-2-yl)-5-(4-(trifluoromethyl)phenoxy)-2-naphthoamide is provided herein. A method for treating cancer is also provided herein, comprising a pharmaceutical formulation in solid dosage form of a therapeutically effective amount of (R)-N-(1-hydroxypropan-2-yl)-5-(4-(trifluoromethyl)phenoxy)-2-naphthoamide.

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.

Described herein are highly loaded, stable solid dosage forms of the plasma kallikrein inhibitor 1-benzyl-1H-pyrazol-4-carboxylic acid 4-formamidinyl benzamide (Compound 1), or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient who would benefit from the action of a plasma kallikrein inhibitor. # imgabs0 #

At present, the most prevalent pharmaceutical dosage forms, the oral immediate-release tablets and capsules, are porous solids of compacted drug and excipient powders. Upon ingestion, physiological fluid percolates the open pores, and the dosage form disintegrates and the drug dissolves. Because the pores in the compacted solids are not well connected, however, fluid percolation generally is not uniform, and the drug release rate is difficult to predict and control. To overcome such limitations, therefore, herein a structured solid dosage form is disclosed. The structured solid dosage form comprises a structural assembly of one or more repeatably arranged, extruded structural elements. The elements comprise segments separated and spaced from adjoining segments by free spacings defining one or more substantially interconnected free spaces, or channels, in the dosage form through which a physiological fluid may percolate. The disclosed dosage form enables more predictable drug release rates, and can be readily manufactured by 3D-printing.

This description relates to oral vaccine dosage forms and processes for producing oral vaccine dosage forms. The dosage forms include lipid-based vesicles (e.g., virosomes, liposomes) that contain an immunogenic quantity of at least one vaccine target molecule, with or without an adjuvant. Specifically, the applicants have discovered a combination of the composition of liquid virosome concentrates, the composition of the base matrix for the solid dosage form formulation (excluding the virosome concentrate), and manufacturing conditions for the dosage forms that can produce a lyophilized sublingual dosage form that has physical robustness, particle integrity, and antigen stability.

The present disclosure provides a solid pharmaceutical composition comprising of tafamidis, a solubilizer, and one or more pharmaceutically acceptable excipients; and process of making such compositions. The present disclosure also provides a solid pharmaceutical composition comprising of tafamidis indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

The present invention relates to a method for preparing immediate and sustained release solid dosage forms, comprising antibodies and functional fragments thereof, by wet granulation, extrusion and spheronization, optionally coated with a delayed release coating the solid dosage forms prepared by the method and the use of the solid dosage forms in the topical treatment in the gastrointestinal tract of a patient.

A screw pump for dispensing a solid dosage form (e.g., a drug or medicament) is configured as a unit for delivering the solid dosage form for dispensing. The screw pump includes a screw including a helical channel. A surface defining the helical channel has a profile at a location along a helical path of the helical channel, the profile being defined in a plane extending along a rotational axis of the screw pump and presenting a recess.